Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Program Accelerates Biomedical Innovations to Market

by Global Biodefense Staff
July 2, 2014

A new collaboration between the National Science Foundation (NSF) and the National Institutes of Health (NIH) will give NIH-funded researchers training to help them evaluate their scientific discoveries for commercial potential with the aim of accelerating the translation of biomedical innovations into applied health technologies.

I-Corps at NIH is a pilot of the NSF Innovation Corps (I-Corps) program specially tailored for biomedical research. Academic researchers and entrepreneurs with Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Phase 1 awards from participating NIH institutes will be eligible to apply to I-Corps at NIH.

The I-Corps curriculum at NIH will be a nine-week boot camp in which experienced, business-savvy instructors work closely with teams of researchers to help them explore potential markets for their federally funded innovations. I-Corps grantees use a hypothesis-validation approach to customer discovery that resonates with scientists and engineers. While I-Corps instructors typically have a wide range of expertise, the I-Corps participants from NIH will be taught by instructors who have biomedical business experience.

“This new collaboration with NIH is further evidence of the flexibility and efficacy of the I-Corps model,” said Pramod Khargonekar, NSF assistant director for Engineering. “Translating basic biomedical research to the marketplace has its own particular set of challenges, which we recognize. By focusing and adapting the I-Corps curriculum to the life sciences, we expect biomedical researchers will be better-equipped to enter the business arena.”

Providing tools for prospective entrepreneurs

Four NIH institutes will participate in the pilot program: the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute, the National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences.

Michael Weingarten, director of the NCI SBIR Development Center, said he and his colleagues initially reached out to NSF because they witnessed the difference I-Corps lessons made for the graduates. To date, more than 300 three-person teams have completed the NSF I-Corps Teams training, including those supported by the Department of Energy’s Advanced Research Projects Agency (ARPA-E).

“I-Corps will help teach NIH-funded start-ups how to build scalable business models around new technologies they’re developing for the detection and treatment of disease,” Weingarten said. “The program sheds new light on how companies can deal with important business risks such as protecting intellectual property and developing regulatory and reimbursement strategies.”

A sustainable innovation ecosystem

In addition to the pilot, existing NIH-funded programs can apply to become new NSF I-Corps sites to broaden the I-Corps network. These programs include the NIH Centers for Accelerated Innovation and Research Evaluation and Commercialization Hubs, which focus on academic researchers with technologies that have not yet led to the formation of a startup or have been licensed by an existing company.

All people and organizations involved in I-Corps become part of the NSF-established National Innovation Network, a nationwide web created to leverage the community that has developed among the grantees to increase the program’s impact.

Source: National Science Foundation press release, adapted. Image credit: NSF. I-Corps at NIH is a trademarked term.

Tags: BiomarkersPOC Diagnostics

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC